GlassScriptPhysician profile
Alpesh Patel
NPI 1003906751
$5,008.57
in general payments reported to CMS, 2019-2025
32 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $31.73 · 2021: $11.60 · 2022: $534 · 2023: $1,762 · 2024: $1,245 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,139 · Education: $120 · Travel and Lodging: $21.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,138.83 |
| Education | $120.12 |
| Travel and Lodging | $21.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,405.30 | 2019-2025 | |
| Janssen Biotech, INC. | $409.48 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Phathom Pharmaceuticals, INC. | $391.99 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $390.71 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $364.35 | 2023-2025 | Entyvio, Eohilia |
| Ironwood Pharmaceuticals, INC | $215.85 | 2022-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $193.21 | 2022-2025 | Dupixent |
| Medtronic, INC. | $188.63 | 2025 | |
| Merck Sharp & Dohme LLC | $188.20 | 2022-2024 | Dificid |
| Boston Scientific Corporation | $148.72 | 2025 | Exalt Model D, Overstitch Endoscopic Suturing System |
| Ardelyx, INC. | $136.63 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $120.05 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $116.26 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $77.86 | 2023-2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $77.31 | 2022-2023 | Ocaliva |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $74.16 | 2022-2023 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Aimmune Therapeutics, INC. | $62.42 | 2024 | |
| Nestle Healthcare Nutrition INC. | $60.82 | 2021-2023 | |
| Daiichi Sankyo INC. | $51.32 | 2022-2025 | Injectafer |
| Amgen INC. | $50.48 | 2022-2023 | Amjevita |
| Madrigal Pharmaceuticals | $44.00 | 2025 | Rezdiffra |
| Biocon Biologics INC | $23.51 | 2025 | Yesintek |
| Mauna Kea Technologies, INC. | $23.41 | 2025 | |
| Sandoz INC. | $20.92 | 2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $20.89 | 2023 | Idacio |
| Alexion Pharmaceuticals, INC. | $19.91 | 2024 | Ultomiris |
| Neurelis, INC. | $19.20 | 2024 | Valtoco |
| Celltrion USA INC. | $15.71 | 2024 | Zymfentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.98 | 2023 | Cyltezo |
| Shionogi INC | $11.70 | 2019 | |
| Erbe USA INC | $2.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alpesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.